| DC23745 |
BAY-2402234
Featured
|
BAY 2402234 (BAY2402234) is a novel potent, selective, orally bioavailable DHODH inhibitor with IC50 of 1.2 nM (human full-length DHODH). |
|
| DC10085 |
Bay 41-4109 (racemate)
Featured
|
BAY 41-4109 racemate is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM. |
|
| DC7323 |
Pritelivir（BAY-57-1293）
Featured
|
BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex. |
|
| DC4113 |
Cinaciguat (BAY 58-2667)
Featured
|
BAY 58-2667 is a nitric oxide (NO)- and heme-independent soluble guanylyl cyclase activator. Displays potent cardiovascular effects. |
|
| DC9783 |
Bay 59-3074
Featured
|
Bay 59-3074 is a novel CB1/CB2 receptor partial agonist (Ki values are 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively). |
|
| DC9578 |
Bay 60-7550
Featured
|
Bay 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human); 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A.
|
|
| DC9632 |
BAY 61-3606 (dihydrochloride)
Featured
|
BAY 61-3606 2Hcl is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
|
|
| DC10660 |
BAY 61-3606 free base
Featured
|
BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase activity (Ki= 7.5 nM) with no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.
|
|
| DC26066 |
BAY 61-3606 hydrochloride
Featured
|
BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase with Ki of 7.5 nM, displays no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src. |
|
| DC9591 |
BAY 80-6946(Copanlisib)
Featured
|
BAY 80-6946(Copanlisib) is a potent and highly selective reversible PI3K inhibitor for PI3Kα/β with IC50 of 0.469 nM/3.72 nM.
|
|
| DC7996 |
BAY 87-2243
Featured
|
BAY 87-2243 is a highly potent and selective inhibitor of hypoxia-induced HIF-1 activation. |
|
| DC23559 |
Bay K-8644
Featured
|
Bay K-8644 is a potent L-type calcium channels (LTCCs) activator with EC50 of 17.3 nM, has positive inotropic, vasoconstrictive and behavioral effects in vivo. |
|
| DC10408 |
BAY1125976
Featured
|
BAY1125976 is a selective allosteric Akt1/2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively. |
|
| DC9679 |
BAY1217389
Featured
|
BAY1217389 is an orally bioavailable, selective inhibitor of the serine/threonine kinase monopolar spindle 1 (Mps1, TTK), with potential antineoplastic activity. |
|
| DC22013 |
BAY-1316957
Featured
|
BAY-1316957 (BAY 1316957) is a highly potent, selective, orally available human prostaglandin E2 receptor subtype 4 (hEP4-R) antagonist with IC50 of 15.3 nM. |
|
| DC20751 |
BAY-1816032
Featured
|
BAY-1816032 (BAY1816032) is a highly potent, selective, orally active BUB1 mitotic checkpoint serine/threonine kinase with IC50 of 7 nM, displays excellent selectivity on a panel of 395 kinases. |
|
| DC10526 |
BAY-1895344 HCl(Elimusertib)
Featured
|
BAY-1895344 is a potent and selective ATM inhibitor. BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride. |
|
| DC26020 |
BAY2335218(BAY-218)
Featured
|
BAY2335218(BAY-218) is the first-in-class AhR antagonist for overcoming tumor-mediated immunosuppression. |
|
| DC12029 |
BAY-299
Featured
|
BAY-299 is a potent and selective inhibitor of the bromodomain and PHD finger-containing (BRPF) family protein BRD1 (IC50 = 6 nM). |
|
| DC10978 |
BAY-3827
Featured
|
BAY-3827 (BAY3827) is a potent, selective inhibitor of AMPK as tool compound to evaluate the therapeutic potential of AMPK inhibition in MYC-dependent tumors; strongly inhibits Acetyl-CoA carboxylase (ACC) phosphorylation in COLO 320DM and IMR-32 cells, but fails to inhibit the proliferation of cells with dysregulated c-MYC or N-MYC. |
|
| DC26010 |
BAY-545
Featured
|
BAY-545 is a novel, potent and selective antagonist of A2B adenosine receptor with an IC50 of 59 nM. BAY-545 also exhibits IC50s of 66, 400, 280 nM for human, mouse, rat A2Badenosine receptor in cells, respectively. |
|
| DC12653 |
BAY-598
Featured
|
BAY-598 is a selective inhibitor of SMYD2. |
|
| DC11218 |
BAY-8002
Featured
|
BAY-8002 is a novel potent, selective, orally available monocarboxylate transporter 1 (MCT1) inhibitor (Kd=7.9 nM). |
|
| DC11505 |
BAY-850
Featured
|
BAY-850 (BAY 850, BAY850) is a potent, isoform selective, cellularly active ATAD2 bromodomain inhibitor with binding IC50 of 166 nM in TR-FRET assay. |
|
| DC10107 |
BAY-876
Featured
|
BAY-876 is the first highly selective GLUT1 inhibitor with IC50 of 0.002 uM. show good metabolic stability in vitro and high oral bioavailability in vivo. |
|
| DC10057 |
Bayer-18
Featured
|
Bayer-18 is a selective TYK2 inhibitor, with an IC50 of 18.7nM on TYK2 as measured by TYK2 HTRF assays. |
|
| DC7372 |
Bazedoxifene-Acetate
Featured
|
Bazedoxifene acetate (TSE 424; WAY-TES 424), a novel selective estrogen receptor modulator (SERM), has been developed to have favorable effects on bone and the lipid profile while minimizing stimulation of uterine or breast tissues. |
|
| DC8922 |
Bazedoxifene
Featured
|
Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment. |
|
| DC20754 |
BC-1215
Featured
|
BC-1215 (BC1215) is a highly unique, selective E3 ligase F box component Fbxo3 inhibitor with IL1β IC50 of 0.9 ug/mL. |
|
| DC10885 |
BCI-121
Featured
|
BCI-121 is a SMYD3 inhibitor that impairs the proliferation of cancer cell. |
|
